Mesa Laboratories Inc: Form 10-Q for the period ended Dec 31, 2020
Filed with the SEC on Feb 3, 2021 and accepted by EDGAR at Feb 3, 2021, 08:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-10-01 to 2020-12-31 | $34.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2020-04-01 to 2020-12-31 | $96.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-10-01 to 2020-12-31 | $13.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2020-04-01 to 2020-12-31 | $33.7m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-10-01 to 2020-12-31 | $20.7m | us-gaap:GrossProfit |
| Gross profit | 9 months2020-04-01 to 2020-12-31 | $62.3m | us-gaap:GrossProfit |
| Research and development | 3 months2020-10-01 to 2020-12-31 | $2.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-04-01 to 2020-12-31 | $7.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-10-01 to 2020-12-31 | $22.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-04-01 to 2020-12-31 | $8.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-10-01 to 2020-12-31 | $1.9m | us-gaap:InterestExpense |
| Interest expense | 9 months2020-04-01 to 2020-12-31 | $5.8m | us-gaap:InterestExpense |
| Income tax | 3 months2020-10-01 to 2020-12-31 | −$1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-04-01 to 2020-12-31 | −$1.9m | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months2020-10-01 to 2020-12-31 | −$0.89 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-04-01 to 2020-12-31 | −$0.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-10-01 to 2020-12-31 | −$0.89 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-04-01 to 2020-12-31 | −$0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-10-01 to 2020-12-31 | 5,125,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-04-01 to 2020-12-31 | 4,922,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-04-01 to 2020-12-31 | $23.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-04-01 to 2020-12-31 | $954.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2020-04-01 to 2020-12-31 | $2.3m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2020-12-31 | $253.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $295.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $621.6m | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $27.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-12-31 | $208.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-12-31 | $412.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-21-001796. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.